Table 4. Comparison between direct sdLDL-C and Sampson sdLDL-C by treatment with statins or pemafibrate in diabetic patients.
| Statins (n = 18) | Pemafibrate (n = 25) | Combined (n = 43) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| before | after | Δ | before | after | Δ | before | after | Δ | |
| TG | 187 (26) | 165 (75) | 22 (74)＊＊＊ | 236 (22) | 133 (74) | 102 (66)＊＊＊ | 216 (112) | 147 (75) | 68 (80)＊＊＊ |
| LDL-C | 125 (24) | 88 (20) | 36 (26)＊＊＊ | 105 (22) | 99 (20) | 5 (15) | 113 (24) | 95 (21) | 18 (25)＊＊＊ |
| Direct sdLDL-C | 54 (10) | 32 (10) | 22 (9)＊＊＊ | 46 (19) | 26 (14) | 20 (11)＊＊＊ | 50 (16) | 28 (13) | 21 (10)＊＊＊ |
| Sampson sdLDL-C | 55 (14) | 38 (9) | 17 (12)＊＊＊ | 51 (18) | 36 (13) | 14 (9)＊＊＊ | 53 (17) | 37 (12) | 15 (10)＊＊＊ |
| ΔsdLDL-C | 0 (14) | 5 (5) | -4 (11)＊＊ | 4 (12) | 14 (9) | -5 (11)＊＊＊ | 2 (13) | 15 (10) | -5 (11)＊＊＊ |
Δ: difference in sdLDL-C (before-after). ＊＊p＜0.01 and ＊＊＊P＜0.0001 (Paired t-test). Plasma lipid levels were also retrospectively studied before and 2-4 months after statin or pemafibrate (0.2 mg/d) administration. Statins used were pitavastatin 1 mg/d (n = 8), atorvastatin 5-10 mg (n = 4), and rosuvastatin (2.5 mg/d) (n = 6).